SequelSEC

Aardvark Therapeutics, Inc. AARD

Pharmaceutical Preparations · CIK 0001774857 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$15.08M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Aardvark Therapeutics, Inc. (AARD) reported revenue of $0 and net income of -$14.39M for the fiscal year ended 2026-06-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Aardvark Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aardvark Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-31
Revenue$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$15.08M-$22.46M-$18.70M-$17.70M-$15.85M-$10.47M
Net income-$14.39M-$21.59M-$17.60M-$16.32M-$14.37M-$9.31M
Research & development$10.46M$16.57M$14.30M$13.74M$13.14M$7.76M
Weighted-average diluted sharesshares 21.85Mshares 21.82MUnavailableshares 21.71Mshares 21.69Mshares 13.19M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.66$-0.99Unavailable$-0.75$-0.66$-0.71
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.63M$5.90M$4.40M$3.97M$2.70M$2.72M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aardvark Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-31
Cash & equivalents$73.85M$62.44M$47.05M$39.28M$26.00M$26.50M
Total assets$81.46M$98.59M$117.18M$133.23M$147.48M$157.02M
Current assets$80.66M$93.58M$111.89M$129.21M$144.77M$154.55M
Total liabilities$6.66M$11.60M$10.55M$10.85M$10.55M$6.34M
Current liabilities$6.39M$11.60M$10.55M$10.74M$10.31M$5.98M
Total equity incl. NCI$74.80M$86.99M$106.63M$122.38M$136.92M$150.69M
Temporary (mezzanine) equityUnavailableUnavailable$0$0$0$0
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.09M$4.49M$2.07M$4.44M$5.06M$2.56M

Cash flow

Aardvark Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-31
Operating cash flow-$17.60M-$18.87M-$16.81M-$16.13M-$9.84M-$11.39M
Capital expendituresUnavailableUnavailable$0$4.00K$91.00K$0
Investing cash flow$28.75M$34.25M$24.30M$29.25M$9.41M-$112.62M
Financing cash flow$262.00K$4.00K$274.00K$171.00K-$71.00K$88.88M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$1.95M$2.00M$1.58M$1.50M$634.00K$233.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$11.00K$11.00K$10.00K$10.00K$11.00K$5.00K

Derived

Aardvark Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-31
Free cash flowUnavailableUnavailable-$16.81M-$16.13M-$9.94MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio12.63x8.06x10.61x12.03x14.04x25.86x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AARD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV ACTU

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.